SAN DIEGO — Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced today the appointment of Jim Mazzola to lead corporate communication and investor relations, reporting to Chief Executive Officer Athena Countouriotis, M.D.
“Jim joins at a pivotal time for the company, and I am very excited to work closely with him again,” said Dr. Countouriotis. “His background complements the strong team we have been building to advance our pipeline, make a difference in the lives of cancer patients and create value for our investors.”
Mr. Mazzola brings nearly 30 years of public relations, financial communication and marketing experience to the company, most recently consulting for several biotechnology and medical-device companies. He previously led communication and investor relations for Halozyme, and before that served as senior vice president of global marketing, communication and investor relations for CareFusion, responsible for the company’s integrated marketing, communication and brand strategy, investor relations, sales operations and serving as president of the CareFusion Foundation. Prior to CareFusion, he was senior vice president of global communication at Cardinal Health, where he led corporate public relations, financial communication and the Cardinal Health Foundation. Earlier in his career, he held communication and marketing communication roles with technology companies Dell Computer and NCR Corp. He earned his bachelor’s degree in communication and M.B.A. from the University of Dayton.
About Turning Point Therapeutics, Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Turning Point Therapeutics, Inc.